Onco Actu du 14 mars 2018

	3.1.1 Prévention - Tabac - e-cigs
Tobacco stick health claims challenged – Expert reaction [Science Media Centre] As outlined in this paper, ‘heat-not-burn’ devices are not without harm. However, they are less harmful than smoking cigarettes (which have over 4000 harmful chemicals in the smoke).
Smokeless cigarettes not as harmless as claimed, study says [The Guardian] Users of new iQOS ‘heat not burn’ devices speed up their ‘puff rate’ to inhale more nicotine, researchers find.
	3.2 Prévention - Obésité
Margaret McCartney: Cancer patients should not be shamed [BMJ Blogs] We need fair information. The risk of cancer from tobacco is a magnitude of between three and four times that of obesity, as Cancer Research UK’s own material shows. And what of the harms of such campaigns? It is ironic that there is so little “awareness” of this. Unless we look systematically for the adverse effects of campaigns like this, we will not see them.
	4. Dépistage, diagnostic et pronostic
AI diagnostics need attention [Nature] Computer algorithms to detect disease show great promise, but they must be developed and applied with care.
‘Digistain’ technology offers revolution in detailed cancer diagnosis [Imperial College] Life-changing treatment decisions have to be based on this ‘grading’ process, yet it is well known that different practitioners given the same slice will only agree on its grade about 70% of the time, resulting in an overtreatment problem. The team's new ‘Digistain’ technology addresses this problem by using invisible mid-infrared light to photograph the tissue slices in a way that maps out the chemical changes that signal the onset of cancer.
	4.2 Dép., diag. & prono. - Génome
At-home genetic testing may be convenient, but it isn’t complete [STAT] Genetic testing can be lifesaving, but it must come with all the facts — which are mounting by the day — and appropriate professional support to help individuals live and plan for the best chance of a healthy life, no matter what the results reveal. That’s something a mail-order kit just can’t do.
	5.12.2 Immunothérapies - CAR-T
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 [Bellicum] With a median follow-up of one year, rates of relapse-free survival and overall survival were 91.5% and 97.3%, respectively. This compares to one-year rates reported in the literature in pediatric AML patients undergoing alternate-donor HSCT of 60% to 80%.
Halted in US by FDA hold, Bellicum buoyed by some positive numbers from its European T cell study for pediatric AML [EndPoints] Right now, Bellicum is doing everything it can to try and make it appear that life and work goes on as normal. But that’s a tough trick for a company which was sent into a tailspin a few weeks ago after regulators halted their US studies of BPX-501 following several cases of brain damage.
	5.2 Pharma
32-Year-Old Professor Raises $50 Million To Make Drugs To Control Genes [Forbes] Its experimental medicines are in the process of lead optimization, meaning that molecules have been developed but need to be improved. Diseases being targeted: synovial sarcoma, but also prostate cancer and non-small cell lung cancer.
	5.2.1 Pharma - Partenariats
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer [Boehringer Ingelheim] Boehringer Ingelheim and Vanderbilt University collaborate to develop novel anti-cancer drugs that inhibit the MCL1 (myeloid cell leukemia 1) protein.
	5.4 Traitements - Economie
SMC nod for Novartis’ Kisqali, MSD’s Keytruda [PharmaTimes] The Scottish Medicines Consortium has published new guidelines approving NHS funding for medicines for breast cancer and Hodgkin’s lymphoma.
The President’s Cancer Panel: Promoting Value, Affordability and Innovation [Patient Power] I was honored to be a part of that panel as one of only two patients out of 26 representative of academia, government, pharmaceutical companies and the insurance industry attending the meetings, and I was the only attendee on active cancer treatment.
Promoting Value, Affordability, and Innovation in Cancer Drug Treatment [President's Cancer Panel] In this report, the President’s Cancer Panel presents recommendations for ensuring alignment of drug prices with their value, promoting use of high-value drugs, and supporting continued innovation in cancer drug development.
	6. Lutte contre les cancers
Data management made simple [Nature] A data-management plan explains how researchers will handle their data during and after a project, and encompasses creating, sharing and preserving research data of any type, including text, spreadsheets, images, recordings, models, algorithms and software.
	6.10.1 Politiques (USA)
‘Right-to-try’ bill rejected by House, in major blow to GOP efforts [STAT] The legislation was rejected by a vote of 259-140. The bill needed two-thirds majority to pass under suspension of rules. The vote was an embarrassing defeat not only for House Republicans but for President Trump, who had called on Congress to quickly pass right-to-try legislation, and Vice President Mike Pence, a longtime supporter of the effort.
	6.11 Patients
I have prostate cancer. But I am happy | George Monbiot [The Guardian] I will ride this out. I will own this disease, but I won’t be defined by it: I will not be prostrated by my prostate. I will be gone for a few weeks but when I return, I do solemnly swear I will still be the argumentative old git with whom you are familiar.
	6.4 Médico-éco
Sky-high prices of everything make US healthcare the world's most expensive [The Guardian] America spends twice as much on health as 10 other rich countries, due to the high cost of everything from prescriptions to doctors.
	6.6 Publications
Latest Reproducibility Project Study Fails to Replicate [The Scientist] Researchers did not observe the same link between a bacterium and human colon cancer that prior investigators had reported.
The retraction process needs work. Is there a better way? [Retraction Watch] We spoke to Fanelli about the new “taxonomy,” and why not everyone is on board.
	6.7 DMP, Big Data & applis
Big Data and Machine Learning in Health Care [JAMA] Machine learning is not a magic device that can spin data into gold, though many news releases would imply that it can. Instead, it is a natural extension to traditional statistical approaches.